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Background: HMLEs (HMLE-SNAIL and Kras-HMLE, Kras-HMLE-SNAIL pairs) serve as excellent model system to
interrogate the effect of SNAIL targeted agents that reverse epithelial-to-mesenchymal transition (EMT). We had earlier
developed a SNAIL-p53 interaction inhibitor (GN-25) that was shown to suppress SNAIL function. In this report, using
systems biology and pathway network analysis, we show that GN-25 could cause reversal of EMT leading to
mesenchymal-to-epithelial transition (MET) in a well-recognized HMLE-SNAIL and Kras-HMLE-SNAIL models.
Results: GN-25 induced MET was found to be consistent with growth inhibition, suppression of spheroid forming
capacity and induction of apoptosis. Pathway network analysis of mRNA expression using microarrays from GN-25
treated Kras-HMLE-SNAIL cells showed an orchestrated global re-organization of EMT network genes. The expression
signatures were validated at the protein level (down-regulation of mesenchymal markers such as TWIST1 and TWIST2
that was concurrent with up-regulation of epithelial marker E-Cadherin), and RNAi studies validated SNAIL dependent
mechanism of action of the drug. Most importantly, GN-25 modulated many major transcription factors (TFs) such as
inhibition of oncogenic TFs Myc, TBX2, NR3C1 and led to enhancement in the expression of tumor suppressor TFs such
as SMAD7, DD1T3, CEBPA, HOXA5, TFEB, IRF1, IRF7 and XBP1, resulting in MET as well as cell death.
Conclusions: Our systems and network investigations provide convincing pre-clinical evidence in support of the
clinical application of GN-25 for the reversal of EMT and thereby reducing cancer cell aggressiveness.
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The epithelial-to-mesenchymal transition (EMT) and the
reverse process, termed the mesenchymal-to-epithelial
transition (MET), plays a central role in cancer progression
and cell death [1]. Cells undergoing EMTare characterized
by their elongated morphology, inherent aggressiveness,
propensity to maintain in long term cell culture conditions
that is reminiscent of stem cell characteristics, which is also
associated with resistance to standard chemotherapies and
targeted therapies [2]. Regimens designed to hit bulk of the* Correspondence: azmia@karmanos.org; fsarkar@med.wayne.edu;
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reproduction in any medium, provided the ortumor cells, in most cases do not eliminate these EMT
sub-population of cells and this has been suggested to be
the underlying cause for drug resistance and tumor recur-
rence [3]. Therefore, targeted elimination of these EMT
cells would be an important prerequisite for achieving opti-
mal results for successful anti-cancer therapy.
SNAIL family of proteins have been shown to play an
important role in the acquisition of malignant (aggressive-
ness) phenotype of epithelial tumors [4]. SNAIL homo-
logues are thought to act as transcriptional repressors and
show a conserved function in mesoderm development
from flies to mammals [5]. Their role in de-lamination
and migration is mediated by triggering the processes that
leads to the acquisition of EMT by directly repressing
the transcription of E-cadherin [6]. Activation of SNAIL
has been shown in pathological specimens at the invasived. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ovarian and in human breast carcinomas [7]. A number of
different signaling pathways such as TGF-β, BMP, FGF and
Wnt signaling have been implicated in the induction of
Snail family members during the process of EMT [8].
Based on its critical role, targeted inhibition of SNAIL pro-
teins has been investigated in pre-clinical setting as a thera-
peutics strategy to reverse EMT phenotype [9].
Even though many different cell models have been de-
veloped that mimic the genotypic and phenotypic charac-
teristics of EMT; however, the Weinberg’s HMLE-SNAIL
models stand out to be very useful among many others
[10]. This is in part due to the fact that EMT induction in
HMLEs is driven by over-expression of a single mesenchy-
mal driver i.e. SNAIL [10]. These and related HMLE cells
have been well characterized for their unique expression
signatures that promote EMT in earlier studies. These
cells have also been shown to form spheroids, maintain
survival in long term cell culture condition, and carry
markers of cancer stem-like cells (over-expression of
Vimentin, ZEB1, TWIST 1 and TWIST 2 and down-
regulation of epithelial markers E-Cadherin) [10]. Therefore,
HMLEs could serve as an excellent tool for investigating
perturbations induced by agents specific towards SNAIL
(SNAIL inhibitors).
Previously, our group has developed a specific SNAIL-
p53 interaction inhibitor GN-25 [11], and this drug was
originally designed to disrupt SNAIL-p53 interaction,
thereby removing the p53-post-translational regulatory
control and rescuing the cell surveillance functions of
this master regulator [12]. GN-25 is cancer cell specific
and does not induce growth inhibition or apoptosis in
normal immortalized cells. In the current study, we found
that GN-25 could reverse the EMT phenotype and could
also induce apoptosis in cancer cells, which prompted us
to further investigate the mechanism of action of GN-25
against HMLE-SNAIL model. In this report, we performed
network analysis using the HMLE-SNAIL models (EMT
phenotypic cells induced by stable transfection with
SNAIL) pre- and post-treatment with a SNAIL inhibitor
GN-25. Our network analysis and biological validation
showed that (a) EMT in HMLE-SNAIL arises through a
complex crosstalk between different mesenchymal pheno-
type promoting networks of pathways, and (b) SNAIL
inhibitor induces a coordinated set of perturbations that re-
align the EMT networks with reversal to MET phenotype.
Results
GN-25 induces growth inhibition in SNAIL-transduced
HMLE cell line models
Structure of GN-25 has been published previously [13].
We performed a time course evaluation of GN-25 induced
morphological changes in HMLE cell pairs. Figure 1
shows that compared to control cells (mesenchymal andelongated, typical feature of EMT phenotypic cells), GN-
25 showed reversal from EMT to Mesenchymal-to-Epi-
thelial Transition (MET) phenotype in the SNAIL and
Kras plus SNAIL transduced HMLE cell lines (epithelial
round cells in higher dose treatments at 24 and 48 hrs).
Next, we investigated GN-25-induced growth inhibition
by MTT assay. As can be seen from the results presented
in Figure 2A, all three cell lines (HMLE-SNAIL, Kras-
HMLE and Kras-HMLE-SNAIL) showed a statistically
significant growth inhibition by GN-25 treatment.
Quercetin a known indirect and weak inhibitor of SNAIL
was used as a positive control and showed growth inhibi-
tory activity at 20 μM concentration.
GN-25 suppresses spheroid formation in SNAIL
transduced HMLE cells
We then investigated whether our drug could suppress
the propensity of SNAIL-Transduced Kras-HMLEs to
form spheroids using sphere-forming assay. As can be
seen from of photomicrographs presented in Figure 2B
(control, DMSO-treated spheres), all cells were able to
grow as spheroids in 3D culture. However, upon 20 μM
GN-25 treatment there was a marked disintegration of
spheres in all three cell lines tested (Figure 2B left panels).
These results clearly showed that SNAIL inhibitor GN-25
not only suppresses growth of HMLEs cells, but also
reduces their ability to form spheroids in 3 D culture.
GN-25 induces apoptosis in HMLE EMT cell models
Once the MET inducing, growth inhibitory and spheroid
suppressive activity of GN-25 against SNAIL transduced
HMLE cell line models were confirmed, we evaluated
whether the drug could induce apoptosis in these cells
using Annexin V FITC and Histone DNA ELISA assay.
As can be seen from the results presented in Figure 3A,
we observed a progressive increase in apoptotic cell
death with increasing concentrations of GN-25 (treated
for 72 hrs) in HMLE-SNAIL (25.1% early stage apop-
tosis), Kras-HMLE (63.5% early stage apoptosis) and
Kras-HMLE-SNAIL (67.8% early stage apoptosis) cells.
Similar results were obtained using the Histone DNA
ELISA assay with the three cells showing a statistically
significant increase in the induction of apoptosis with in-
creasing doses of GN-25 (Figure 3B). These results sug-
gest that GN-25 not only reverses EMT phenotype but
this is also accompanied by the induction of apoptosis in
the HMLE cells.
Effect of SNAI2 siRNA on GN-25 activity
As SNAIL is the primary target of GN-25, we investigated
how the GN-25 drug compared with the effects of
SNAIL-targeted siRNA on the induction of apoptosis. As
can be seen from the results presented in Figure 3C, the
apoptotic potential of GN-25 was similar to that of control
Figure 1 GN-25 reverses EMT phenotype. HMLE-SNAIL, Kras-HMLE and Kras-HMLE-SNAIL cells were exposed to different concentrations of
GN-25 as indicated and incubated for 24 and 48 hrs. Photomicrographs were taken using light microscope at different time points. Note:
GN-25 resulted in growth inhibition as well as caused reversal of EMT phenotype to epithelial phenotype.
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when combined with GN-25 appears to enhance the de-
gree of apoptosis. In Kras-HMLE cells (that have not been
transduced with SNAIL), the siRNA treatment did not en-
hance the activity of the drug. These results provided the
proof-of-concept showing that SNAIL protein is a direct
target of GN-25. However, further in-depth analysis is
needed to analyze what apparently constitute the broader
effects of GN-25 treatment in order to understand the
genes and functions that are deregulated during the rever-
sal of EMT to MET after treatment with GN-25, and for
which microarray and pathway modeling experiments
were performed.
Systems-level analyses of gene expression level changes
induced by GN-25 treatment specifically in SNAIL-
transduced HMLE cell lines
Microarray experiments and analyses (described in detail
under Methods), were carried out to identify significantgene expression level changes that were uniquely affected
by GN-25 treatment in the context of the transformed
SNAIL over-expressing cell line, Kras-HMLE-SNAIL,
compared to GN-25 effects in the control Kras-HMLE cell
line. The net result showed a set of 2,737 genes (function-
ally annotated gene transcripts) with corresponding Kras-
HMLE-SNAIL expression ratios (GN-25-treated versus
vehicle control) (Additional file 1: Figure S1). The genes
were examined in the follow-up systems-level analyses
using Ingenuity Systems® software (Redwood, CA) to in-
vestigate the predicted on-target impact of GN-25 treat-
ment and to infer additional downstream targets and
broader biological consequences of GN-25 treatment in
the SNAIL transduced cells. A global gene ontology ana-
lysis using Ingenuity Systems® software predicted that
GN-25 treatment showed decreased activation state for a
significant functional annotations including formation of
cellular protrusions, transformation, migration of tumor
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Figure 3 GN-25 induces apoptosis in HMLE cells. HMLE cells were exposed to different concentrations of GN-25 as indicated and incubated
for 72 hrs. Apoptosis was evaluated using Annexin V FITC assay (A) and Histone DNA ELISA assays (B). Values are representative of three
independent experiments. (C) Cells were incubated with either scrambled siRNA or SNAI2 siRNA (Santa Cruz Biotechnology) for 24 hrs according
to previously published methods [26], siRNA silenced cells were seeded at a density of 50,000 cells per well in six well plate and further exposed
to GN-25 (20 μM) for additional 72 hrs. Apoptosis was evaluated using Histone DNA ELISA assay. Graphs are representative of three independent
experiments. ** represents statistically significant p < 0.01 when compared to GN-25 alone treatment.
Figure 2 GN-25 induces growth inhibition and suppresses spheroid formation in SNAIL-transduced HMLE models. (A) HMLE-SNAIL, Kras-HMLE
and Kras-HMLE-SNAIL cells were exposed to different concentrations of GN-25 or Quercetin as + ve control as indicated and incubated for 72 hrs. Growth
inhibition was evaluated using MTT assay. (B) Cells were allowed to grow as spheroids as described under Methods section. Once established, the
spheroids were exposed to GN-25 (20 μM). Note: GN-25 suppresses growth and sphere-forming capacity of Snail-HMLEs. Figures are representative of
three independent experiments.
Azmi et al. BMC Systems Biology 2013, 7:85 Page 4 of 11
http://www.biomedcentral.com/1752-0509/7/85
Azmi et al. BMC Systems Biology 2013, 7:85 Page 5 of 11
http://www.biomedcentral.com/1752-0509/7/85all are consistent with the conclusion that GN-25 reverses
the EMT or rather induces MET phenotypic and geno-
typic changes. Gene expression data were queried to see if
GN-25 treatment impacted known EMT-associated fac-
tors in Kras-HMLE-SNAIL cells specifically. Of eleven
known EMT-associated genes compiled from the litera-
ture, six were identified among the genes that were signifi-
cantly up-regulated or down-regulated by treatment with
GN-25 in Kras-HMLE-SNAIL cells—they are SNAIL
family members SNAI1 and SNAI2, and TWIST family
members TWIST1 and TWIST2 (Figure 4A). The down-
regulation of SNAI2, TWIST1 and TWIST2 is consistent
with evidence that TP53 down-regulates TWIST expres-
sion and, in turn, down-regulates SNAI2 expression. We
can only speculate that the up-regulation of SNAI1 may
be the result of a feedback mechanism that up-regulates
SNAI1 when signaling resulting from SNAIL/TP53BA
Figure 4 The expression of EMT factors is changed by GN-25 treatme
identified among genes that showed a significant LogRatio detection p-va
heat map of Log2 gene expression ratios shows how many EMT-associated
treatment Kras-HMLE-SNAIL cells with GN-25 across four biological replicate
regulated by GN-25 treatment in Kras-HMLE-SNAIL cells as determined by t
versus vehicle control in Kras-HMLE-SNAIL and Kras-HMLE cells (p ≤ .001, Be
functional relationships for these genes and a substantial number of others
mapped in the interaction network where the edges between genes repre
Systems’ curated knowledgebase data set.interaction is inhibited by GN-25. The regulatory relation-
ships for these genes and a substantial number of others
from the Kras-HMLE-SNAIL-specific data set that are
functionally associated with them are mapped in the inter-
action network in Figure 4B where the edges between
genes represent data and peer reviewed results contained
in the Ingenuity Systems’ curated knowledgebase.
In additional analysis we looked specifically at GN-25
-induced expression level changes and the predicted ac-
tivity state for transcription factors in Kras-HMLE
-SNAIL-unique data set. The transcription factor activity
prediction tool in the Ingenuity Systems® software uses
an algorithm that weighs the direction of transcript level
changes in the data set of interest and an empirical data-
base to elucidate the genes that are likely regulated by a
given transcription factor. A regulation z-score and stat-
istical test are factored into a prediction for thent in Kras-HMLE-SNAIL cells. (A) Six EMT-associated genes were
lue in an Agilent two-color gene expression microarray (p ≤ .001). The
genes were up-regulated (red) or down-regulated (green) by
s. Genes with an asterisk (*) were among those shown to be uniquely
he ANOVA analysis that compared response to GN-25 treatment
njamin-Hochberg FDR multiple test correction p≤ .05). (B) The
linked to them from the Kras-HMLE-SNAIL-specific data set are
sent data and peer-reviewed results contained in the Ingenuity











TBX2 -2.005 Inhibited -2.978 1.91E-04
MYC -2.245 Inhibited -2.912 1.52E-08
NR3C1 -3.751 Inhibited -2.654 1.21E-08
TWIST1 -4.096 Inhibited -2.028 3.92E-02
GLI1 2.264 Activated 2.073 3.00E-02
SMAD7 2.005 Activated 2.079 4.17E-06
DDIT3 8.076 Activated 2.110 1.06E-02
CEBPA 4.142 Activated 2.189 9.86E-05
HOXA5 3.132 Activated 2.189 1.27E-01
TFEB 2.098 Activated 2.339 3.92E-02
IRF1 3.651 Activated 2.506 2.84E-02
XBP1 2.026 Activated 3.415 4.11E-01
IRF7 3.915 Activated 3.894 1.32E-04
TP53 NS Activated 3.502 4.57E-18
Transcription factors whose expression levels (fold-change, treated versus untreated) and predicted activation state are significantly changed by GN-25 treatment
in HMLE-SNAIL cells specifically compared to HMLE cells. Although the expression levels of TP53 was not significantly (NS) changed by GN-25 treatment in HMLE-
SNAIL cells, its function was predicted to be inhibited in untreated HMLE-SNAIL cells, but activated by GN-25 treatment. Myc-target genes in the data set
significantly overlap with a gene set with clinical outcome (dead at 3 years) (Additional file 3: Table S2). GN-target genes in the data set overlap significantly with
the 3 year clinical outcome metastatic outcomes. Oncomine query matching VV and Koa, respectively.
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flects the numbers of target gene candidates that are
changed in the experiment data set and the number of
those that are changed in a direction consistent with the
Ingenuity Systems’ database. According to the results
presented in Table 1, TP53 is predicted to be activated
by GN-25 treatment, which is consistent with the on-
target effect of GN-25 mediated disruption of the
SNAIL/TP53 protein-protein interaction. Furthermore,
TWIST1 is predicted to be inhibited, which correlates
with the observed down-regulation of TWIST1 expres-
sion and the down-regulation of TWIST1 target
SNAI2. Furthermore, the analysis revealed that GN-25
treatment of the Kras-HMLE-SNAIL transformed cells
was very likely inhibiting MYC and glucocorticoid re-
ceptor (NR3C1) transcription factors and their related
functional outcomes. Figure 5 displays the MYC-
regulated gene expression network predicted to be
inhibited by GN-25 treatment in Kras-HMLE-SNAIL
cells. A greater understanding of possible cancer rele-
vance for these discoveries came from subsequent ana-
lysis using Oncomine™ [14]. Uploading the list of the
identified MYC-regulated genes from the analyzed data
set into a survey of the Oncomine™ database revealed
that the MYC-targeted genes in the data set signifi-
cantly overlapped with gene sets associated with an ex-
ceptionally poor prognosis, including breast cancer
clinical outcome i.e. dead at 3 years (Additional file 3:
Table S2).Biological validation of network genes at expression level
Once the GN-25 induced network signatures were
obtained, we validated the expression of their constitu-
ents by confocal microscopy and western blot analysis.
As can be seen from results in Figure 6A, GN-25 treat-
ment resulted in condensed expression of Vimentin
(on nuclear envelope) and suppression of SNAIL ex-
pression in HMLE-SNAIL and Kras-HMLE-SNAIL
cells. Most importantly, suppression of EMT markers
was concurrent with re-expression of E-Cadherin
(Lower panels). In western blot experiments we ob-
served suppression of EMT markers in both HMLE-
SNAIL and Kras-HMLE-SNAIL cells Figure 6B. The
major drivers of EMT, i.e. TWIST1 and TWIST2 were
suppressed with progressive increasing concentrations
of GN-25. On the other hand the expression levels of
epithelial marker E-cadherin and EGFR were found to
be up-regulated. The results clearly demonstrate that
GN-25-induced growth inhibitory, MET and apoptosis
outcomes coincide with reversal of the expression of
EMT factors and re-expression of epithelial-associated
factors.
Discussion and conclusion
Here we report, for the first time, the network analysis
and biological validation of the EMT reversing perturba-
tions induced by a SNAIL inhibitor GN-25 in the HMLE-
based model system. Using systems level investigations,
we showed that GN-25 induces MET and consequently
Figure 5 Genes in the Kras-HMLE-SNAIL-specific data set linked to Myc function. Genes that are differentially and significantly regulated by
GN-25 treatment in Kras-HMLE-SNAIL cells specifically compared to Kras-HMLE cells that are associated with Myc transcription factor function.
Perspective is fold-change (treated/untreated), red up-regulated, green down-regulated. From Ingenuity Systems® analysis.
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transduced HMLE cells through coordinated suppression
of EMT network genes. Our findings also highlight the
role of a number of secondary players that cumulatively
support GN-25’s mechanism of action. These findings
demonstrate that the successful design of drugs against
EMT should not only be focused on EMT specific genes
but additional secondary networks that may require a pro-
miscuous targeting by drugs that have pleiotropic mode of
action.
EMT confers mesenchymal properties to epithelial
cells, and this has been closely associated with aggres-
siveness of carcinoma cells [15]. Emerging research
shows that EMT programs are orchestrated not by one,
but a set of pleiotropically acting transcription factors
(TFs) [16]. The actions of these EMT-TFs enable the
propensity for early steps of metastasis; local invasion
and subsequent dissemination of carcinoma cells to dis-
tant sites. The genetic and epigenetic mechanisms that
regulate the activation of EMT-TFs and the traits they
induce are areas under intensive investigation. Such
studies are expected to provide new opportunities for
therapeutic intervention and may help to overcome
tumor heterogeneity and therapeutic resistance.
The discovery and development of HMLE cell line
models were facilitated through introduction of hTERT,
which encodes the catalytic subunit of the humantelomerase holoenzyme, as well the SV40 early region
[10]. Additionally, introduction of EMT promoting
genes such as snail and twist in these models facilitated
the reprogramming of the transduced and transformed
HMLE cells to give rise to EMT phenotype [10]. These
developments have helped to molecularly, understand
the basis of this complex phenomenon. This has, in turn,
driven the research on pharmaceutical strategies that
target reversal of EMT. Nevertheless, EMT is a complex
process arising from the de-regulations in complex bio-
logical networks [17]. These EMT biological networks
cannot be investigated in isolation (using reductionist
approaches), and thus it requires advanced, holistic and
systems level analyses. This is especially needed in order
to develop drugs that reverse EMT.
While Weinberg’s EMT cell line models have been the
subject of individual-set of differentially expressed (DE)
gene analyses using the t-test and the F-test, these are
still insufficient knowledge to interrogate the EMT
phenomena, which is in part due to the presence of
additional genes that do not meet the DE criteria. Such
analysis cannot extract EMT-specific characterization
of mesenchymal pathway genes; i.e. identifying the
distinguishing set of mesenchymal patterns in the en-
tire co-expressed gene groups that may be specific to
EMT only. Additionally, to date there are no drug re-





































Figure 6 Biological validation of expression datasets at the protein level. (A) Confocal analysis of HMLE-SNAIL and Kras-HMLE-SNAIL cells
post GN-25 treatment. Cell were exposed to indicated concentrations of GN-25 for 24 hrs in 4 well chambered slides and immunofluorescence
assay was performed according to published methods . Slides were stained with either vimentin (cell signaling), Snail (Cell signaling) or E-
Cadherin (cell signaling) antibodies overnight. Secondary Antibody staining was performed for 2 hrs using anti-mouse Alexafluor antibody
(Invitrogen). (B) Western blot analysis of HMLE-SNAIL and Kras-HMLE-SNAIL cells exposed to indicated concentrations of GN-25 for 24 hrs. The
blots were probed for TWIST1, TWIST2 and E-Cadherin. GAPDH was used as a loading control. Blots are representative of two
independent experiments.
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works. Here, we showed a network-based differential
analysis model for analyzing the topological differences
between two gene networks constructed from the ex-
pression data from GN-25 treated cells. We selected
Kras-HMLE-SNAIL over HMLE-SNAIL for our net-
work analysis since earlier it was shown that Kras
transforms HMLE cells and drives SNAIL expression
through the activation of Gli [10]. Supporting this no-
tion, Morel and colleagues have shown that sequential
retroviral-mediated expression of the telomerase cata-
lytic subunit (giving rise to HMEC/hTERT cells), SV40
large T and small t antigens (HMLE cells) and an onco-
genic allele of H-Ras, H-RasV12 (HMLER cells)accelerates EMT [18]. This allowed us to ask two ques-
tions: (1) what are the networks modulated in response
to our SNAIL inhibitor, and (2) is there a compensa-
tory influence of oncogenic Ras on GN-25 activity.
Our in-depth network analyses provided insights for
multiple factors that are involved in what can be consid-
ered on-target drug predictions (e.g., the functional up-
regulation of certain transcription factors resulted from
GN-25 treatment) consistent with what is known about
EMT. The analysis also presented broader secondary
downstream or pleiotropic effects of the drug that may
enhance its effectiveness in reversing EMT. Further, the
analysis points to pathways where de novo or acquired
resistance mechanisms may be the important route.
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design guided solely by presumed targets and differen-
tially expressed genes may not be successful in reversing
EMT due to the presence of multiple factors that func-
tion together to reinforce the phenotype. However, as
shown by our network results, agents such as GN-25,
with far-reaching effects (i.e. with inherent network
pharmacology properties), can better serve the purpose in
reversing EMT phenotype by not only directly targeting
an assumed target and differentially expressed genes, but
also secondary yet important signaling pathways or func-
tional networks. In conclusion, our network investigations
provided convincing pre-clinical rationale in support of
the clinical application of GN-25 and related agents for
the treatment of EMT cells in order to overcome thera-
peutics resistance of aggressive and metastatic cancers.
Methods
Cell lines and culture conditions, and research reagents
SNAIL-transduced HMLEs (HMLE-SNAIL, Kras-HMLE
and Kras-HMLE-SNAIL) were generously provided by
Dr. Robert Weinberg, Whitehead Institute, Massachusetts.
SNAIL inhibitor GN-25 was developed as documented
previously [11]. Quercetin; an indirect inhibitor of SNAIL
was purchased from SIGMA (St Louis USA). Primary
antibodies for SNAIL, Vimentin, TWIST1 and TWIST2
were purchased from Cell Signaling (Danvers, MA). All
the secondary antibodies were obtained from Sigma
(St. Louis, MO).
Cell growth inhibition by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay (MTT)
SNAIL-transduced HMLE cells were seeded at a density
of 5 × 103 cells per well in 96-well micro-titer culture
plates. After overnight incubation, medium was removed
and replaced with fresh medium containing GN-25 at in-
dicated concentrations (0–25 μM) diluted from a 10 mM
stock or Quercetin (used as positive control at 20 μM).
After 72 hours of incubation, MTT assay was performed
by adding 20 μL of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) Sigma (St. Louis,
MO) solution (5 mg/mL in PBS) to each well and incu-
bated further for 2 hours. Upon termination, the super-
natant was aspirated and the MTT formazan formed by
metabolically viable cells was dissolved in 100 μL of iso-
propanol. The plates were gently rocked for 30 minutes
on a gyratory shaker, and absorbance was measured at
595 nm using a plate reader (TECAN, Durham, NC).
Sphere formation/disintegration assay
Briefly, single-cell suspensions of HMLE-SNAIL, Kras-
HMLE and K-ras-HMLE-SNAIL were plated on ultra–
low adherent wells of 6-well plates (Corning) at 1,000 cells
per well in sphere formation medium (1:1 DMEM/F12medium supplemented with B-27 and N-2; Invitrogen).
After 7 days, the spheres were collected by centrifugation
(300 xg, 5 minutes) and counted. The proportion of
sphere-generating cells was calculated by dividing the
number of spheres by the number of cells seeded. Single-
cell suspensions of spheres were plated at 500 cells per
well in the sphere formation medium. After 1 or 3 weeks
of incubation with GN-25, secondary spheres were
harvested for counting as described above. For sphere dis-
integration assay, 1,000 cells per well on ultra–low adher-
ent wells of 6-well plate were incubated for a total of
10 days following 5 days of drug treatment, and the cells
were harvested as described previously [19]. The spheres
were collected by centrifugation and counted under a
microscope as described above.
Quantification of apoptosis by histone DNA ELISA and
annexin V FITC assay
Cell Apoptosis was detected using Annexin V FITC
(Biovision Danvers MA) and Histone DNA ELISA Detec-
tion Kit (Roche, Life Sciences) according to the
manufacturer's protocol. HMLE cells were seeded at a
density of 50,000 cells per well in six-well plates in 5 ml of
corresponding media. 24 hrs after seeding the cells were
exposed to GN-25 at different concentrations for 72 hrs.
At the end of treatment period cells were trypsinized and
equal numbers were stained with Annexin V and
Propidium Iodide. The stained cells were analyzed using a
Becton Dickinson flow cytometer at the Karmanos Cancer
Institute Flow cytometry core. The second apoptosis assay
quantifies histone-complexed DNA fragments (mono-
and oligonucleosomes) from the cytoplasm of cells after
the induction of apoptosis or when released from necrotic
cells. Since the assay does not require pre-labeling of cells,
it can detect internucleosomal degradation of genomic
DNA during apoptosis. All procedures were performed
according to our previously published protocol [20].
Immunofluorescence and confocal microscopy
Cells were grown on glass chamber slides and exposed
to GN-25 at indicated concentrations for 24 hrs. In
another set of experiments, at the end of the treatment
the cells were fixed with 10% paraformaldehyde for
20 min. The fixed slides was blocked in TBST and
probed with primary and secondary antibody according
to our previously published methods [21]. The slides
were dried and mounting medium was added to it and
covered with a coverslip and were analyzed under an
inverted fluorescent microscope. A total of three inde-
pendent experiments were performed.
Western blot analysis
HMLE-SNAIL and Kras-HMLE-SNAIL cells were grown
in 100 mm petri-dishes over night to ~70% confluence.
Azmi et al. BMC Systems Biology 2013, 7:85 Page 10 of 11
http://www.biomedcentral.com/1752-0509/7/85Next day, cells were exposed to indicated concentrations
of GN-25 for 24 hrs followed by extraction of protein
for western blot analysis. Preparation of cellular lysates,
protein concentration determination and SDS-PAGE
analysis was done as described previously [22].
siRNA and transfection
To study the effect of SNAIL silencing on activity of GN-
25, we utilized siRNA silencing technology. SNAI2 siRNA
and control siRNA were obtained from Santa Cruz
Biotechnology. Cells were transfected with either control
siRNA or SNAIL siRNA for 24 hrs using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s proto-
col. All procedures have been standardized and published
previously [23]. After the siRNA treatment period, cells
were further treated with GN-25 (at IC50 concentration)
in 96-well plates for MTT and 6-well plates for Annexin V
FITC assays, respectively. Knock-down efficiency was
evaluated by western blot analysis.
Microarrays and gene expression data analysis
K-ras-HMLE-SNAIL cells were plated so that they
reached 75% confluence after 3 days. At this point, cul-
tures were treated with or without GN-25 (15 μM).
Total RNA was isolated from four sets of parallel plated
culture plates, treated with or without GN-25, at
24 hours after the addition of inhibitor. Media was
changed the day after plating and at the start of treat-
ment. Total RNA quantity and quality was determined
by analysis using the NanoDrop 1000 and Agilent
Bioanalyzer (Agilent Technologies). All analyzed samples
had RIN scores ≥ 7. Whole-genome expression levels
were analyzed by a two-color microarray-based ap-
proach. A treated and untreated sample for one cell line
was combined and hybridized to Agilent 4x44k human
arrays and scanned with the Agilent G2505B microarray
scanner system. Data quality was assessed, and data were
processed by Agilent Feature Extraction software that
produced expression data measures including LogRatio
expression levels, LogRatio Error and P Value LogRatio.
Features included in further analysis were annotated,
gene-level that passed a p Value LogRatio cut-off ≤ 0.001.
ANOVA analysis and multi-test correction (Benjamin-
Hochberg p ≤ 0.05) was done using Partek software to
compare the 2 sets of 4 two-color arrayed replicates (the 2
sets were Kras-HMLE and Kras-HMLE-SNAIL cell lines),
to identify gene expression level changes (≥2 fold-change)
that were uniquely affected by GN-25 treatment in the
context of SNAIL-transduced Kras-HMLE cell line com-
pared to GN-25 effects on the expression in the Kras-
HMLE cell line (ANOVA p ≤ 0.001). The net result was a
set at 2,737 genes, and corresponding HMLE-SNAIL ex-
pression ratios (GN-25-treated versus vehicle control) that
were examined in follow-up systems-level analyses.Availability of supporting data
The supporting microarray data is publicly available and
can be freely accessed at the following link: http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE44397.
Additional files
Additional file 1: Figure S1. Overview of gene expression microarray
results. (A) Histogram showing distribution of log ratio of gene
expression in 4 biological replicates of two cell lines (GN25-treated/
untreated) measured by two-color Agilent assay. The histogram
demonstrates that a greater number, and higher gene expression
changes occurred in SNAIL overexpressing KRAS-HMLE-SNAIL cells than
in KRAS-HMLE cells (HMLE-SNAIL, blue versus HMLE, red). (B) Comparison
of numbers of gene transcripts showing significant change in each cell
line due to treatment with GN25 (p≤.001; FC≥2; NCBI refseq and
ENSEMBL transcripts). From the 2973 gene transcripts unique to the
KRAS-HMLE-SNAIL context, 2737 were functionally annotated. These were
used in subsequent systems-level analyses to investigate functional
interaction networks and signaling pathways affected by GN-25
treatment.
Additional file 2: Table S1. Predicted downstream functional effects
due to GN-25 treatment of KRAS-HMLE-SNAIL cells. Analysis of
significantly changed genes differentially affected by GN-25 in KRAS-
HMLE-SNAIL cells compared to KRAS-HMLE cells. From an enrichment
analysis with Ingenuity Systems® software (Redwood, CA).
Additional file 3: Table S2. Results from gene set comparisons in
OncomineTM. The identified MYC-regulated genes significantly changed
with GN-25 treatment in the KRAS-HMLE-SNAIL-specific data set (known
myc-regulated genes in KRAS-HMLE-SNAIL) were used to survey of the
Oncomine™ database. The results revealed that the MYC-targeted genes
in the analyzed data set significantly overlapped with genes associated
with an exceptionally poor prognosis in the database.
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